VALBIOTIS announces the efficacy of LIPIDRIVE® is confirmed in three preclinical models and the recruitment for Phase I/II, first study in humans, is being finalized.
consolidated results for the first half of 2017September 29th 2017
VALBIOTIS consolidated results for the first half of 2017 and major progress in clinical studies.
International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory BoardSeptember 20th 2017
VALBIOTIS announced the arrival of Jean ZETLAOUI on Valbiotis’ Supervisory Board.
VALBIOTIS: Pascal SIRVENT appointed Director of Discovery and Preclinical ResearchSeptember 14th 2017
VALBIOTIS announced the arrival of Pascal SIRVENT as Director of Discovery and Preclinical Research from September 1st, 2017.